Pertuzumab for the Neoadjuvant Treatment of Early-Stage HER2-Positive Breast Cancer: An Evidence Review Group Perspective of a NICE Single Technology Appraisal

Squires, H. orcid.org/0000-0002-2776-4014, Pandor, A., Thokala, P et al. (5 more authors) (2017) Pertuzumab for the Neoadjuvant Treatment of Early-Stage HER2-Positive Breast Cancer: An Evidence Review Group Perspective of a NICE Single Technology Appraisal. Pharmacoeconomics. ISSN 1170-7690

Abstract

Metadata

Authors/Creators:
Copyright, Publisher and Additional Information: © Springer International Publishing AG 2017. The final publication is available at Springer via http://dx.doi.org/10.1007/s40273-017-0556-7.
Dates:
  • Published (online): 2 August 2017
Institution: The University of Sheffield
Academic Units: The University of Sheffield > Faculty of Medicine, Dentistry and Health (Sheffield) > School of Medicine (Sheffield) > Division of Genomic Medicine (Sheffield) > Department of Oncology (Sheffield)
The University of Sheffield > Faculty of Medicine, Dentistry and Health (Sheffield) > School of Health and Related Research (Sheffield) > Sheffield Centre for Health and Related Research
Depositing User: Symplectic Sheffield
Date Deposited: 09 Aug 2017 08:30
Last Modified: 02 Aug 2018 00:38
Published Version: https://doi.org/10.1007/s40273-017-0556-7
Status: Published online
Publisher: Springer Verlag
Refereed: Yes
Identification Number: https://doi.org/10.1007/s40273-017-0556-7
Related URLs:

Share / Export

Statistics